SCHEMBL2170733

SCHEMBL2170733

NC(=O)N(C1CCCC1)C1CCCC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 4/20 0.43
PHGDH O43175 1/20 0.41
HSD11B1 P28845 2/20 0.40
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
ALOX15 P16050 1/20 0.37
ALOX12 P18054 1/20 0.37
RECQL P46063 1/20 0.37
ADAM17 P78536 1/20 0.37
KMT2A Q03164 1/20 0.37
EPHX1 P07099 3/20 0.37
S1PR1 P21453 1/20 0.36
ADH1A P07327 3/20 0.36
ADH1C P00326 2/20 0.36
S1PR3 Q99500 2/20 0.35
TSHR P16473 1/20 0.35
GAA P10253 1/20 0.35
ADH4 P08319 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2754 0.97 ALOX5 (0.45) ALOX5PHGDHHSD11B1KDM4EMEN1
SCHEMBL19458771 0.97 ALOX5 (0.45) ALOX5PHGDHHSD11B1KDM4EMEN1
SCHEMBL11234464 0.97 ALOX5 (0.45) ALOX5PHGDHHSD11B1KDM4EMEN1
SCHEMBL2606404 0.97 ALOX5 (0.45) ALOX5PHGDHHSD11B1KDM4EMEN1
SCHEMBL9547539 0.97 ALOX5 (0.44) ALOX5PHGDHHSD11B1KDM4EMEN1
Hydrochloric Acid SCHEMBL13518199 0.95 ALOX5 (0.43) ALOX5PHGDHHSD11B1KDM4EMEN1
Urea SCHEMBL2807369 0.95 ALOX5 (0.43) ALOX5PHGDHHSD11B1KDM4EMEN1
Cyclohexylamine SCHEMBL27429394 0.89 ALOX5 (0.39) ALOX5PHGDHHSD11B1KDM4EMEN1
SCHEMBL9427489 0.88 ALOX5 (0.39) ALOX5HSD11B1
SCHEMBL2606335 0.87 EPHX1 (0.38) ALOX5PHGDHHSD11B1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346834-A1 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-07-27 EP claimed
WO-2010034657-A1 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed
WO-2024043261-A1 AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME 日本化薬株式会社 2024-02-29 WO disclosed
US-20230019461-A1 POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2023-01-19 US disclosed
CN-110945083-B Styrene compound or salt thereof, polarizing film, polarizing plate and display device 日本化药株式会社 2022-07-01 CN disclosed
EP-3998502-A1 POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE Nippon Kayaku Kabushiki Kaisha (JP) 2022-05-18 EP disclosed
CN-114026199-A Polarizing luminescent film, polarizing luminescent sheet, and display device containing water-soluble coumarin compound or salt thereof 日本化药株式会社 2022-02-08 CN disclosed
CN-110945083-A Styrene compound or salt thereof, polarizing film, polarizing plate and display device 日本化药株式会社 2020-03-31 CN disclosed
US-10343438-B2 Heat-sensitive recording material NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2019-07-09 US disclosed
US-20170297355-A1 Heat-Sensitive Recording Material NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2017-10-19 US disclosed
EP-2346834-A1 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-07-27 EP disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-7772271-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
WO-2010034657-A1 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO disclosed
EP-1984332-A2 METHODS FOR TREATING HEPATITIS C PTC Therapeutics, Inc. (US) 2008-10-29 EP disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299068-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS ALOX5 2791/4885PHGDH 2460/4885HSD11B1 2007/4885
US-20170297355-A1 Heat-Sensitive Recording Material SCN1A, SCN3A, KCNN3 ALOX5 3449/4885PHGDH 1628/4885HSD11B1 3940/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS ALOX5 2791/4885PHGDH 2460/4885HSD11B1 2007/4885
US-10343438-B2 Heat-sensitive recording material SCN1A, SCN3A, KCNN3 ALOX5 3449/4885PHGDH 1628/4885HSD11B1 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.